Can Nektar Therapeutics cover its short-term obligations?

Its current ratio is 10.21 — current assets exceed current liabilities.

Where does Nektar Therapeutics's balance sheet data come from?

Every line is extracted from Nektar Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Nektar Therapeutics NKTR Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Cash and cash equivalents	$5.7M-20.0%	$3.2M-67.5%	$11.35M+81.7%	$6.33M-38.9%	$7.12M+31.3%
Short-term investments	$419.03M+133%	$230.64M+9.3%	$229.18M+6.9%	$132.92M-45.4%	$179.74M-25.3%
Prepaid expenses and other current assets	$20.44M+81.2%	$20.51M+238%	$11.15M+24.8%	$10.66M+28.6%	$11.28M+5.0%
Total current assets	$589.04M+156%	$266.27M+1.9%	$281.36M-1.8%	$186.57M-36.8%	$229.91M-28.1%
Other non-current assets	$11.24M+108%	$14.14M+204%	$5.16M+14.1%	$5.02M+16.5%	$5.39M+15.8%
Available-for-sale securities	$162.99M+7,973%	$0-100%	$0-100%	$0—	$2.02M—
Total assets	$763.27M+198%	$280.41M-7.7%	$301.35M-2.1%	$207.53M-39.6%	$256.24M-35.3%
Accounts payable	$10.03M-43.8%	$10.77M-6.8%	$15.56M+81.5%	$14.28M+121%	$17.83M+104%
Accrued expenses	$5.01M-0.4%	$2.94M-90.2%	$8.61M+22.8%	$6.55M-24.9%	$5.03M-31.9%
Operating lease liabilities, current	$22.53M+3.2%	$20.5M+3.2%	$22.18M+3.2%	$22.01M+3.2%	$21.84M+12.8%
Total current liabilities	$57.71M-18.6%	$53.54M-12.8%	$66.34M-1.8%	$71.39M+24.5%	$70.93M+35.3%
Operating lease liabilities, non-current	$60.63M-22.8%	$65.26M-21.1%	$69.73M-19.6%	$74.15M-18.3%	$78.5M-17.1%
Other non-current liabilities	$8.45M+25.0%	$8.63M+19.1%	$5.03M-27.3%	$5.64M-30.0%	$6.76M+55.9%
Total liabilities	$187.06M-22.9%	$190.57M-21.6%	$216.26M-16.5%	$231.75M-12.1%	$242.5M-10.0%
Preferred stock	$0—	$0—	$0—	$0—	$0—
Common stock	390M+30.0%	390M+38,999,900%	390M+30.0%	300M0.0%	300M0.0%
Additional paid-in capital	$4.38B+19.6%	$3.85B+5.2%	$3.81B+4.2%	$3.67B+0.5%	$3.66B+0.5%
Retained earnings	-$3.81B-4.3%	-$3.76B-4.6%	-$3.72B-3.4%	-$3.69B-3.4%	-$3.65B-3.8%
Accumulated other comprehensive income (loss)	-$1.03M-2,751%	$17K-72.1%	$56K-84.2%	-$14K+97.2%	$39K+110%
Total stockholders' equity	$576.22M+4,094%	$89.83M+47.9%	$85.09M+74.1%	-$24.21M-130%	$13.74M-89.2%
Total liabilities and stockholders' equity	$763.27M+198%	$280.41M-7.7%	$301.35M-2.1%	$207.53M-39.6%	$256.24M-35.3%
Available-for-Sale Debt Securities - Amortized Cost	——	——	——	——	——
Available-for-Sale Debt Securities - Unrealized Loss Position (>=12 Months)	——	——	——	——	——
AFS and Trading Securities - Unrealized Loss Position (>=12 Months)	——	——	——	——	——
AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Fair Value	——	——	——	——	——
Cash, Cash Equivalents, and Marketable Securities	$694.16M—	$216.5M—	$219.93M—	——	——
Available For Sale Securities Debt Securities Current	$419.03M+133%	$230.64M+9.3%	$229.18M+6.9%	$132.92M-45.4%	$179.74M-25.3%
Other current assets	$20.44M+81.2%	$20.51M+238%	$11.15M+24.8%	$10.66M+28.6%	$11.28M+5.0%
Deferred Tax Assets and Other Non-Current Assets	$11.24M+108%	$14.14M+204%	$5.16M+14.1%	$5.02M+16.5%	$5.39M+15.8%
Investments - Amortized Cost Basis	——	——	——	——	——
Long-term marketable securities	$162.99M+7,973%	$0-100%	$0-100%	$0—	$2.02M—
Other Assets	——	——	——	——	——
Other non-current assets	$11.24M+108%	$14.14M+204%	$5.16M+14.1%	$5.02M+16.5%	$5.39M+15.8%
Software and Technology Licenses, Net	$11.24M+108%	$14.14M+204%	$5.16M+14.1%	$5.02M+16.5%	$5.39M+15.8%
Accrued Litigation	$0—	$0—	$0—	$0—	$0—
Accrued Manufacturing Costs	$5.01M-0.4%	$2.94M+3.8%	$8.61M+22.8%	$6.55M-24.9%	$5.03M-31.9%
Other Commercial Liabilities	$25.15M-19.5%	$22.27M-25.7%	$28.59M-11.7%	$35.1M+18.9%	$31.25M+28.7%
Accrued Liabilities, Current	$25.15M-19.5%	$22.27M-25.7%	$28.59M-11.7%	$35.1M+18.9%	$31.25M+28.7%
Compensation and benefits	$5.01M-0.4%	$2.94M+3.8%	$8.61M+22.8%	$6.55M-24.9%	$5.03M-31.9%
Total debt	$83.16M-17.1%	$85.75M-16.4%	$91.92M-15.1%	$96.16M-14.2%	$100.34M-12.0%
AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Accumulated Loss	——	——	——	——	——
Common Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Common Stock Shares Issued	29.5M-84.8%	29.5M+128%	19.7M-89.8%	13M-93.2%	194.4M+1.3%
Convertible Preferred Stock Authorized Shares	10M0.0%	10M0.0%	10M0.0%	10M0.0%	10M0.0%
Convertible Preferred Stock Outstanding Shares	0—	0—	0—	0—	0—
Additional paid-in capital	$4.38B+19.6%	$3.85B+5.2%	$3.81B+4.2%	$3.67B+0.5%	$3.66B+0.5%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$3K-84.2%	$2K+100%	$2K-89.5%	$1K-94.7%	$19K0.0%
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	$0—	$0—	$0—
Preferred Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Unrealized Gains on Investments	——	——	——	——	——
Unrealized Losses on Investments (Before Tax)	——	——	——	——	——
Cumulative Cost Basis	——	——	——	——	——
Accrued Contract Termination Costs Current	$3.07M+8.5%	$2.63M-4.9%	$3.15M-0.1%	$3.28M-2.4%	$2.83M-7.2%
Accrued Research And Development Expenses Current	$13.02M+10.2%	$13.98M—	$12.08M—	$15.45M—	$11.82M—
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	——	——	——	——	——
Gross Unrealized Gains	——	——	——	——	——
Total	——	——	——	——	——
Available for sale investments	$694.16M—	$216.5M—	$219.93M—	——	——
Available For Sale Securities In Unrealized Loss Positions Number Of Positions Less Than One Year	——	——	——	——	——
Cash Restricted Cash Cash Equivalents And Available For Sale Investments	$731.6M+232%	$245.75M-8.7%	$270.21M+8.5%	$175.9M-39.5%	$220.65M-32.3%
Common stock, par value (in dollars per share)	$00.0%	$00.0%	$00.0%	$00.0%	$00.0%
Common stock, shares authorized (in shares)	$390M+30.0%	$390M+30.0%	$390M+30.0%	$300M0.0%	$300M0.0%
Common stock, shares issued (in shares)	$29.47M-84.8%	$29.47M+128%	$19.65M-89.8%	$13.01M-93.2%	$194.39M+1.3%
Common Stock, Shares, Outstanding	$20.38M-89.0%	$20.38M+64.5%	$19.65M-89.3%	$12.46M-93.2%	$186.1M+1.4%
12 months or more	——	——	——	——	——
Goods And Service Tax Refunds Repayment Due	——	——	——	——	——
Liability Related To Sale Of Potential Future Royalties Non Current	$60.27M-30.2%	$63.16M-31.2%	$75.16M-23.2%	$80.57M-25.1%	$86.32M-26.8%
Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs	$60.27M-30.2%	$63.16M-31.2%	$75.16M-23.2%	$80.57M-25.1%	$86.32M-26.8%
Estimated litigation liability	$0—	$0—	$0—	$0—	$0—
Other accrued liabilities	$4.06M-65.0%	$2.72M-72.6%	$4.76M+10.5%	$9.83M+54.0%	$11.58M+39.4%
Preferred Stock, Par or Stated Value Per Share	$00.0%	$00.0%	$00.0%	$00.0%	$00.0%
Preferred Stock Share Designated	0—	0—	0—	0—	0—
Preferred Stock, Shares Authorized	$10M0.0%	$10M0.0%	$10M0.0%	$10M0.0%	$10M0.0%
Preferred Stock, Shares Outstanding	$0—	$0—	$0—	$0—	$0—

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Can Nektar Therapeutics cover its short-term obligations?: Its current ratio is 10.21 — current assets exceed current liabilities.
Where does Nektar Therapeutics's balance sheet data come from?: Every line is extracted from Nektar Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.